J2G-MC-JZJC: LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506783-14-00

Acronym

J2G-MC-JZJC

Enrollment

Registered

2024-05-15

Start date

2020-02-24

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Brief summary

PFS per REIST 1.1 by BICR

Interventions

DRUGCARBOPLATIN

DRUGCISPLATIN

DRUGSELPERCATINIB

DRUGPEMBROLIZUMAB

DRUGPEMETREXED

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS per REIST 1.1 by BICR	—

Countries

Belgium, France, Germany, Greece, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026